We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-8.52%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$853M
AUM Growth
-$177M
Cap. Flow
+$51M
Cap. Flow %
5.98%
Top 10 Hldgs %
71.46%
Holding
37
New
3
Increased
4
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$27.3M
2
TVRD
Tvardi Therapeutics
TVRD
+$25.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.2M
4
MRSN
Mersana Therapeutics
MRSN
+$8.06M
5
NRIX icon
Nurix Therapeutics
NRIX
+$6.1M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$20.1M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$9.59M
3
OMEG
Omega Alpha SPAC Class A Ordinary Shares
OMEG
+$3.93M
4
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
2 Financials 3.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.03M 0.71%
626,442
– –
NAUT icon
27
Nautilus Biotechnolgy
NAUT
$114M
$5.38M 0.63%
2,000,000
– –
APTX
28
DELISTED
Aptinyx Inc. Common Stock
APTX
$4.96M 0.58%
8,891,758
– –
SLDB icon
29
Solid Biosciences
SLDB
$971M
$4.88M 0.57%
528,661
– –
PANA
30
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.57%
500,000
– –
ARYE
31
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$4.86M 0.57%
500,000
– –
BLSA
32
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.83M 0.57%
487,500
– –
FLACU
33
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$2.96M 0.35%
300,000
– –
XFOR icon
34
X4 Pharmaceuticals
XFOR
$425M
$2.91M 0.34%
100,651
– –
SYRE icon
35
Spyre Therapeutics
SYRE
$9.18B
$2.7M 0.32%
213,908
+100,000
+88% +$3.5M
OMEG
36
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
– –
-400,000
Closed -$3.93M
JYAC
37
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-300,000
Closed -$2.95M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q2 2022 Portfolio in Review

As of Q2 2022, Bain Capital Life Sciences Investors held 37 positions worth $853M, down 17% from $1.03B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Bain Capital Life Sciences Investors deployed $51M of net new capital in Q2 2022, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Protagonist Therapeutics: 2,260,572 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $20.1M trimmed.

  • Bain Capital Life Sciences Investors's largest Q2 2022 buy was Protagonist Therapeutics: 2,260,572 shares worth $17.9M.
  • Bain Capital Life Sciences Investors added most to Mersana Therapeutics in Q2 2022, an estimated $8.06M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2022 reduction was Arcutis Biotherapeutics, cutting an estimated $20.1M.
  • Bain Capital Life Sciences Investors fully exited Omega Alpha SPAC Class A Ordinary Shares in Q2 2022, selling an estimated $3.93M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 71% of its $853M portfolio in Q2 2022.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q2 2022.
  • Bain Capital Life Sciences Investors's portfolio value fell 17% quarter-over-quarter to $853M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2022, filed 15 Aug 2022.